THER
THERALINK TECHNOLOGIES
stockOTC
theralink technologies, inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapy products. the company has proprietary rights to immunotherapy platform focusing on prostate and breast cancers. the company's lead product is proscavax, which is in phase 2 clinical trials for the treatment of prostate cancer. it is also developing targeted therapies. theralink technologies, inc. has a partnership with perthera, inc. to facilitate and enhance access to theralink's 32 phosphoprotein panel, the theralink assay, for breast cancer patients. the company was formerly known as oncbiomune pharmaceuticals, inc. and changed its name to theralink technologies, inc. in september 2020. theralink technologies, inc. is based in baton rouge, louisiana.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 2Y | 0.00 | 2024-10-08 | -99.00% | — |
| 5Y | 1.61 | 2022-02-25 | -100.00% | -33.106 |
THERALINK TECHNOLOGIES (OTC:THER) stock price today is $0.00, and today's volume is 1,026,798. THER is up 0.000% today. The 30 day average volume is 482,999. THER market cap is $6,151 with 6.15B shares outstanding.